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ABSTRACT
Recently, vaginal douching has been associated with many health risks in women. The aim of this
study was to analyze the effect of commercial douche products against various vaginal microor-
ganisms, including lactobacilli. Seven commercial douches were tested against eight Lactobacillus
clinical isolates and three type strains from the American Type Culture Collection. BV-associated
bacteria included six strains of five genera: Gardnerella, Mobiluncus, Mycoplasma, Peptostreptococcus,
and Ureaplasma. Two isolates of group B Streptococcus, and three species of Candida were also
tested. The minimal inhibition concentrations and minimal contact times for these products against
vaginal microorganisms were determined in broth cultures. Four antiseptic-containing douche
products showed a strong inhibitory effect against all vaginal microorganisms tested with a short
contact time (less than 1 min). Three vinegar-containing douche products selectively inhibited vaginal
pathogens associated with bacterial vaginosis, group B streptococcal vaginitis, and candidiasis, but not
lactobacilli. The antimicrobial effects ofthe commercial douche products varied among different brands
and microbial species tested. Infect. Dis. Obstet. Gynecol. 8:99-104, 2000. (C) 2000 Wiley-Liss, Inc.
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he vaginal ecological system constitutes a large
population of diverse microorganisms. Under
healthy conditions, lactobacilli dominate this popu-
lation, preventing other potentially harmful micro-
organisms from colonization or overgrowth,z Lac-
tobacilli produce factors including lactic acid, hy-
drogen peroxide, and various bacteriocins, which
may tend to exclude other microbes in the same
environment. Therefore, factors that inhibit or
eliminate lactobacilli may facilitate colonization or
overgrowth of potentially pathogenic microorgan-
isms in the vagina.
Vaginal douching has a long history and is prac-
ticed regularly by many American women and ado-
lescent girls.
3-6 However, little is known about the
risks versus personal benefits of this practice. Many
clinical studies suggest a possible association be-
tween douching and various health risks in women.
These include pelvic inflammatory disease,7,s bac-
terial vaginosis (BV),9-11 chlamydia, le and other
sexually transmitted infections including HIV, 13-1s
miscarriages, 16 premature birth of low birth-weight
infants, 17 ectopic pregnancy, ls,19 and cervical can-
cer.2o
Although most published data argue against
douching,7-2 two studies indicated that douching
might be medically beneficial.2-2e First, douching
may significantly eliminate semen after sexual in-
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tercourse. This may decrease both the retention
time and load of sexually transmitted pathogens in
the vagina,el Second, by comparing douching and
HIV prevalence in women,ez a study showed that
douching with commercial antiseptic preparations
is associated with a lower prevalence of HIV, but
douching with noncommercial preparations is asso-
ciated with a higher prevalence of HIV. Therefore,
in addition to the flushing effect, the ingredients of
douche solutions may also be critical.
Because douching may disrupt the balance of
vaginal microbial ecology, its inhibitory effects on
vaginal microorganisms, including the commensal
lactobacilli, need to be studied. A prior in vitro
study using only lactobacilli and antiseptic douche
solutions showed that the douches might kill vagi-
nal lactobacilli,z3 Another in vivo study tested more
vaginal microorganisms, but it only analyzed two
douche preparations,z4 Because the vaginal flora
contains many different microorganisms in addition
to lactobacilli, and because the composition of
douche products varies from brand to brand, stud-
ies with more douche products and a more com-
plete spectrum of vaginal microorganisms are
needed to evaluate the association between douch-
ing and vaginal health. In the present study, there-
fore, we tested in vitro a range of vaginal microor-
ganisms, including vaginal lactobacilli and
pathogens associated with BV, vaginal candidiasis
(VC), and group B streptococcal vaginitis, in re-
sponse to seven douche products common to the U.S.
market. Among these products, some contained dif-
ferent antiseptics, and some contained none.
MATERIALS AND METHODS
Seven vaginal douche products were purchased
from local department stores or drug stores in the
United States. Each product was arbitrarily as-
signed an alphabetical letter. The ingredients of
these products as indicated on their boxes are pre-
sented in Table 1. Their pH values were measured
and are also listed in Table 1. The ingredients of
douche B were mixed immediately before use.
The ingredients of douches F and G were similar;
the difference was that douche G contained addi-
tional dyes and fragrance.
The vaginal microorganisms used in this study
included a group of normal flora, lactobacilli, and
three groups of pathogenic floras: BV-associated
TABLE I. Ingredients of vaginal douche
products tested
Product Ingredients listed on the package pH
Water, vinegar, octoxynol 9, sorbic acid 3.0
Medicated douche solution with 3.5
Povidone-iodine, final conc. 0.3%
Purified water, sodium chloride, dibasic 7.2
sodium phosphate, methyl-paraben,
disodium-EDTA, monobasic sodium
phosphate, sodium lauril sulfate,
propylparaben (post-menstrual)
Purified water, vinegar, benzoic acid 3.0
Purified water, sodium citrate, citric acid, 4.0
vinegar
Purified water, sodium citrate, citric acid, 4.0
vinegar, diazolidinyl urea, octoxynol-9,
cetylpyridinium chloride, edetate
disodium
Purified water, sodium citrate, citric acid, 4.2
SD alcohol 40, diazolinidyl urea,
octoxynol-9, fragrance, cetylpyridinium
chloride, edetate disodium, D&C Red
#28, FD&C Blue #1
apH of the products was not indicated on the packages.
bacteria, group B streptococci, and VC-associated
Candida species. To compare the effect of douche
products on different vaginal Lactobadllus species,
we tested a group of lactobacilli, including eight
clinical isolates from a previous study es and three
type strains from American Type Culture Collec-
tion (ATCC). The group of BV-associated bacte-
riae6 included six strains of five genera from ATCC.
These included two strains of Gardnerella vaginalis,
one strain each of the remaining species, elobilun-
cus curtisii subsp, curtisii, Peptostreptococcus tetradius,
Mycoplasma hominis, and Ureaplasma urealyticum.
Additionally, two strains of group B streptococci
(from Dr. Crag Rubens at University of Washing-
ton, Seattle) and three species of Candida were also
included. A complete list of the microorganisms is
shown in Table 2. Multiple species and strains of
each group were used for the study in order to
compare the range of their sensitivities to various
douche products.
The inhibitory effect of the douche products
against vaginal microflora were determined by two
previously described methods,z3 The first method
measured the minimal inhibitory concentration
(MIC) of each douche solution (after proper dilu-
tion) required to inactivate individual testing mi-
croorganisms. The second method measured the
minimal contacting time (MCT) of each douche
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TABLE 2. Minimal inhibitory concentration (MIC, in percentage) of seven commercial douche products against
vaginal microorganisms in vitro
Douche product
Species Strains A B C D E F G
Lactobacilllus clinical isolates
Lactobacillus-type strains
L. gasseri
L. jensenii
L. vaginalis
BV-associated bacteria
G. vaginalis
G. vaginalis
M. curtisii
M. hominis
P. tetradius
U. urealyticum
Group B streptococci
S. agalactiae
S. agalactiae
Candida species
C. albicans
C. tropicalis
C. glabrata
KC 005b 50 50 50 50 NE 3.12 3.12
KC 007a 50 50 25 50 NE 3.12 3.12
KC 008 50 NE 50 NE NE 3.12 3.12
KC 013 50 50 50 50 NE 6.25 3.12
KC 018b NE NE NE NE NE 3.12 1.56
KC 021 50 50 25 50 NE 3.12 3.12
KC 035a 50 50 50 50 NE 6.25 6.25
KC 039 50 50 50 50 50 6.25 6.25
ATCC 9857 50 50 50 50 50 6.25 6.25
ATCC 25258 NE NE 50 NE NE 6.25 6.25
ATCC 49540 50 50 25 50 50 3.12 3.12
ATCC 14018 25 25 25 50 50 0.39 0.39
ATCC 49145 50 50 25 50 50 0.78 0.78
ATCC 35241 50 50 25 50 50 0.39 0.39
ATCC 23114 25 25 25 50 50 3.12 3.12
ATCC 35098 25 50 25 50 50 1.56 1.56
ATCC 27168 25 50 12.5 50 50 0.78 0.78
A909 Type IA 25 50 12.5 50 50 0.39 0.39
091-2 50 50 50 50 50 1.56 1.56
ATCC 10231 50 50 12.5 50 50 12.5 12.5
ATCC 13803 NE NE 12.5 NE 50 12.5 12.5
ATCC 66032 NE NE 25 NE NE 25 25
aNE, No inhibitory effect at the maximal concentration (50%.) tested.
solution at solution at full strength without dilution
required to inactivate these microorganisms. The
inhibitory effect of these douche preparations
against vaginal microflora were determined in two
different broth media. Lactobacilli were cultured
in the Lactobacilli MRS broth (pH 5.5). The BV-
and VC-associated pathogens and the group B
streptococci were cultured in the Brain Heart In-
fusion broth (Difco, Detroit, MI)(pH 7.4), supple-
mented with 5% horse serum, hemin (5 pg/ml) and
vitamin K1 (1 ng/ml).
To measure MIC, each bacterial or yeast culture
was grown in appropriate medium to mid-
exponential phase. The cultures were centrifuged
at 5,000 rpm for 5 min and washed in phosphate-
buffered saline (PBS). Each vaginal douche solu-
tion was 2-fold serially diluted (from 50 to 0.09%)
with appropriate broth medium. The washed bac-
terial or yeast cells were then inoculated into these
different dilutions of broth-douche mixtures at 106
colony-forming unit (cfu)/ml. The results for bac-
terial growth were observed with a spectrophotom-
eter at OD6oo after incubation at 37C for 24 h
under anaerobic condition. The MIC was deter-
mined by the lowest concentration of the diluted
douche solution that inhibited bacterial growth.
To measure MCT, actively growing bacterial or
yeast cultures in mid-exponential phase were cen-
trifuged at 5,000 rpm for 5 min and washed in phos-
phate-buffered saline (PBS). The PBS with pH 6.5
was used to wash lactobacilli, whereas the PBS
with pH 7.3 was used to wash pathogens. The
washed cells were resuspended in an undiluted
douche solution at a final concentration of 106 cfu/
ml. The cells resuspended in PBS were used as
controls. At different time intervals (0, 1, 5, 10, 15,
20, and 30 min), 0.5-ml aliquots of microorganism-
douche suspension were removed, washed in PBS,
and resuspended in appropriate broth medium. Af-
ter anaerobic incubation at 37C for 24 h, the
growth of each culture was determined with a spec-
trophotometer at OD6oo.
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TABLE 3. Minimum contact times (MCT, in minutes) of seven douche products required to inhibit the growth
of vaginal microorganisms in vitro
Douche product
Species Strains A B C D E F G
Lactobacillus clinical isolates
KC 005b NE <
KC 007a 10 <
KC 008 15 <
KC 013 5 <
KC 018b NE <
KC 021 15 <
KC 035a 5 <
KC 039 15 <
Lactobacillus-type strains
L. gasseri ATCC 9857 30 <
L. jensenii ATCC 25258 30 <
L. vaginalis ATCC 49540 NE <
BV-associated bacteria
G. vaginalis ATCC 14018 < <
G. vaginalis ATCC 49145 < <
M. curtisii ATCC 35241 < <
M. hominis ATCC 23114 < <
P. tetradius ATCC 35098 < <
U. urealyticum ATCC 27168 30 <
Group B streptococci
S. agalactiae A909 Type IA 5 <
S. agalactiae 091-2 5 <
Candida species
C. albicans ATCC 10231 NE <1
C. tropicalis ATCC 13803 NE <1
C. glabrata ATCC 66032 30 <
NE NE <
NE NE <
NE NE <
NE NE <
NE NE <
NE NE <
NE NE <
NE NE <
<1 NE NE <1 <
<1 NE NE <1 <
<1 NE NE < <
<1
<1
5
<1
<1
<1
<1
5
<1
<1
NE
NE
NE
inh.
inh.
inh.
inh.
<1
5
<1
<1
NE
NE
NE
inh.
inh.
NE
<1
<1
<1
<1
5
<1
<1
<1
<1
<1
aNE, no inhibitory effect on microbial growth after 30 mi.n of contact with the douche at full strength.
birth., the growth was suppressed, but microorganisms were not killed after 30 min of exposure.
RESULTS
The pH values of the seven vaginal douche solu-
tions were determined and listed in Table 1. The
pH values ranged from 3.0 to 4.2, except douche C,
which was 7.2. The MIC values of the seven
douche products against all microorganisms tested
are presented in Table 2.
For douches A to E, the MIC values against
lactobacilli were relatively high, ranging from 25%
to no effect. However, douches F and G exhibited
much lower MIC values against the same testing
organisms, ranging between 1.56% and 6.25%.
Douches A and B (medicated with povidone-iodine
at a final concentration of 0.3%) showed no signifi-
cant effect on the Lactobacillus strains tested.
Douches C and D showed no detectable effect
against most microorganisms tested. The slight in-
hibitory effect of douche C on some vaginal Lacto-
bacillus strains may be due also to its higher pH
(7.2) as compared with the rest of products tested
(pH range between 3.0 and 4.2). In general, the
MIC values of these douche products against lac-
tobacilli varied from strain to strain.
The MIC values of these douche solutions for
BV-associated pathogens were lower than those for
lactobacilli. The MIC values for douches A to E
varied from 12.5% to 50%. The medicated douche
B, designed for use by women with vaginitis symp-
toms, showed no significant differences from the
effects of douches A, C, D, and E. Although
douche C had a higher pH value, it was more ef-
fective against BV-associated pathogens than was
the medicated douche B. Douches F and G exhib-
ited significant antibacterial and antifungal activi-
ties against all microorganisms tested. The two G.
vaginalis strains showed different sensitive patterns
to these douche products tested. In general, the
three yeast cultures were less sensitive to these
douche products tested.
The MCT results are presented in Table 3. The
contact time intervals were selected to simulate the
actual presence of the douche solution in the va-
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gina. The douche products were tested at full
strength without dilution. Douches B, C, F, and G
required less than min to kill all of the tested
Lactobacillus strains, BV-associated pathogens,
group B streptococci, and 2 of 3 yeast cultures in
vitro. No apparent effect on growth of lactobacilli,
group B streptococci and U. urealyticum was ob-
served after exposure to douches D and E for up to
30 min. Interestingly, douches D and E killed most
BV-associated pathogens tested. They killed (7.
vaginalis, P. tetradius, and Mycoplasma hominis upon
contact for less than 1 min, and 31obiluncus curtisii
upon contact for less than 5 min. These two
douches also inhibited in vitro the growth of the
three Candida species tested. Although douche A
suppressed many lactobacilli after 5 to 30 min of
exposure, it more effectively inhibited BV-
associated pathogens (less than min) and group B
streptococci (5 min). But it had virtually no effect
on yeasts.
DISCUSSION
Recent clinical studies suggested that women who
frequently douche are associated with an increased
risk of pelvic inflammatory disease, 7,8 BV,9-1 chla-
mydia,e and other sexually transmitted infections,
including HIV, 13-1s miscarriages,
6 premature birth
of low birth-weight infants,7 ectopic preg-
nancy, 8-19 and cervical cancer,z Nonetheless,
datae, ee that support douching exist. These in-
clude elimination of semen after sexual contact. As
a result, it may decrease the retention time and
load of sexually transmitted pathogens, presumably
reducing the risk of contracting sexually transmit-
ted diseases. Clearly, the effect of douching is con-
troversial, and the mechanism is unknown. Several
possibilities might have compromised the research
results. First, in some women, douching may be in
response to vaginal discomfort caused by preexist-
ing infections. Second, douching may be associated
with a high level of sexual activity, which by itself
can be a risk factor for vaginal infection.3 Third,
douching itself may increase the risk of vaginal in-
fection possibly by disturbing vaginal ecology.
Because douching may alter the vaginal ecology
by inhibition of the vaginal commensal bacteria, we
tested the antimicrobial effects of seven commer-
cial douche products against a list of microorgan-
isms by two assay methods: MIC and MCT. The
MCT assay can directly measure the antimicrobial
effects of the douche products,z In comparison
with MCT, the classical MIC assay might not re-
flect the actual performance of the douche activity
because a douche solution could not remain in the
vagina over a 24-hour period, the time used to
evaluate inhibition in an MIC assay. But the MIC
result can provide information on the antimicrobial
potency of various douche products. This informa-
tion is important because many douche products
with different antimicrobial potencies may gener-
ate similar MCT results under in vitro assay con-
ditions. Therefore, results from both assays (Tables
2 and 3) may provide complementary information
for better evaluation of the potential antimicrobial
effect of these douche products.
The results showed that the three products
(douches A, D, and E) made of water, vinegar, and
other ingredients, had no effect (or mild effect for
douche A) on the growth of vaginal lactobacilli, but
selectively inhibited multiple vaginal pathogens
(Table 3). Four products (douches B, C, F, and G)
made of various antiseptics showed a significant
inhibitory effect against all vaginal microorganisms
tested, including vaginal lactobacilli, BV-associated
pathogens, group B streptococci, and three Candida
species. Based on these results, therefore, douch-
ing might have a varied effect depending upon
what product is used and what vaginal conditions
exist.
Because most studies7-z have associated douch-
ing with various health risks, consumers should be
aware that certain douche products may have a
negative effect on the vaginal microflora and thus
may be harmful to women’s health. For women
who elect to douche, it may be important to choose
an individually appropriate product according to
their vaginal health status. We speculate that if a
woman with a healthy, Lactobacillus-dominant va-
gina douches with a solution containing antiseptics,
her lactobacilli can be eliminated and other bacte-
ria may colonize and overgrow. On the other hand,
if a woman does not have vaginal lactobacilli, or if
she already has an infection, a douche product con-
taining antiseptics may conceivably help decrease
the vaginal load of infecting bacteria. We also
speculate that after the antimicrobial treatment, it
may be helpful to apply a second product to facili-
tate the reestablishment of vaginal lactobacilli--
perhaps a Lactobadllus vaginal suppository or acid
gel.
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In summary, this in vitro study suggested that
the antimicrobial effects of the commercial douche
products varied among different brands and micro-
bial species tested. The antiseptic-containing
douche products inhibited all microorganisms
tested. The vinegar-containing products selec-
tively inhibited pathogens associated with vaginal
infections, but not vaginal lactobacilli.
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